Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Revance Therapeutics, Inc. is not a good value stock. Revance Therapeutics, Inc. is not a good growth stock. Revance Therapeutics, Inc. is not very popular among insiders. Revance Therapeutics, Inc. is a mediocre stock to choose.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the developme...

News

Certuity LLC Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Zolmax Certuity LLC purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund...\n more…

Comparing Revance Therapeutics (NASDAQ:RVNC) & Praxis Precision Medicines (NASDAQ:PRAX)

Zolmax Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) and Revance Therapeutics (NASDAQ:RVNC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will...\n more…

Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

Ticker Report StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Free Report) in a report released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical...\n more…

StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)

Zolmax StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a "hold" rating on the...\n more…

Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

Ticker Report StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Free Report) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company's...\n more…

How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%

Zacks Investment Research Shares of Revance Therapeutics, Inc. (RVNC) have gained 74.1% over the past four weeks to close the last trading session at $6.58, but there could still be a solid upside left in the stock if...\n more…